Welcome Visitor, Sign Up for Free!

Onglyza Study Boosts Stock

Onglyza is a prescription drug used to treat type II diabetes. It is considered a DPP-4 inhibitor that diabetics use to help regulate their blood pressure. It is also known as “incretin mimetics”, meaning it is a chemical that acts as an insulin-copycat in order to stimulate the pancreas to produce more insulin. It is recommended that the person taking Onglyza eats a healthy diet and exercises to improve blood sugar levels. AstraZeneca is the pharmaceutical company that produces Onglyza. In addition,  AstraZeneca has a collaboration agreement with Bristol-Myers Squibb Company for the drug.

AstraZeneca has been presented with evidence that Onglyza can cause pancreatitis and even pancreatic cancer.


The recent study could be the reason for AstraZeneca’s stock growth. Onglyza revenues as recorded by AstraZeneca were $102 million in the second quarter of 2013, reflecting an increase of 28% over the year-ago period.

AstraZeneca’s Onglyza Study

AstraZeneca recently announced a full data from the SAVOR study on the diabetes drug, Onglyza. The study was a randomized, double-blind, placebo-controlled study that evaluated Onglyza in patients with a history of cardiovascular disease or multiple risk factors.

The study concluded that the primary composite endpoint of cardiovascular death, non-fatal MI or non-fatal ischemic stroke occurred in 7.3% of the patients in the Onglyza arm as compared to 7.2% in the placebo arm.

Onglyza did not present itself to be exceptionally superior to the placebo with respect to an endpoint that including cardiovascular death, non-fatal myocardial infarction (:MI) or non-fatal ischemic stroke. However, the drug met the primary safety objective of non inferiority to placebo for the same composite endpoint.